BioGaia Protectis® When diarrhea strikes, it can turn a child's world upside down.

A comprehensive approach is vital to restoring their health and reducing the duration of diarrheal episodes in children.



# Globally, diarrheal diseases are among the leading causes of mortality and morbidityin children under 5 years of age.<sup>1,2</sup>

- 3<sup>rd</sup> leading cause of death<sup>2</sup>
- 9% global mortality in children in 2021<sup>2</sup>
- Kills 1200 children every day<sup>2</sup>

The impact of diarrhea is multifaceted.



Excessive diarrhea can disrupt the balanceof gut bacteria, creating a vicious cycleof diarrhea and dysbiosis<sup>.5-8</sup>



Guidelines endorse usage of probiotics for effective diarrheal management in children.

WHO/UNICEF ESPGHAN and ESPID recommendations<sup>4,9,1</sup> Strategy to combatacute diarrhea in children

ORS + Zinc + Continued feeding\* + Probiotics

Probiotics recommended for diarrhea management in children are, Lacticaseibacillus rhamnosus GG, Saccharomyces boulardii, Limosilactobacillus reuteri (L. reuteri)DSM 17938.

ESPGHAN and ESPID recommendations<sup>10,11</sup>

8 global guideline recommendations<sup>10-16, 42</sup> L. reuteri DSM 17938 is a recommended probiotic for diarrheal managementas an adjunct to ORS.

\*Continued feeding with breast milk or regular formula.

ESPGHAN: European Society for Paediatric Gastroenterology, Hepatology and Nutrition ESPID: European Society of Pediatric Infectious Diseases; *L. reuteri: Limosilactobacillus reuteri* ORS: Oral rehydration solution

UNICEF: United Nations International Children's Emergency Fund; WHO: World Health Organization.

## *L. reuteri* DSM 17938 is a powerful yet gentle probiotic to treat watery diarrhea and prevent new episodes of diarrhea.

Action of L. reuteri DSM 17938 in infant diarrhea<sup>17-19</sup>

Treat watery diarrhea

Reduces duration and frequency of diarrheal episodes

Antimicrobial effect

Restricts the growth of pathogenic gut microorganisms



Gut and immune health

Improves intestinal health and enhances immune response

Microbiota modulation

Positive effect of microbiota composition

The number of diarrhea patients in the *L. reuteri* group was significantly lower on days 1 and 2 compared to the control group.<sup>20</sup>

# BioGaia Protectis® contains *L. reuteri* DSM 17938, which positively impacts gut health and recovery from diarrhea.

*L. reuteri* DSM 17938 offered rapid relief from diarrheal symptoms within 48 hours



\*L. reuteri Protectis® group received supplementation of 1×10<sup>8</sup> CFU L. reuteri DSM 17938 daily for 5 days.

#L. reuteri Protectis® group received five drops containing 1×10<sup>8</sup> CFU L. reuteri DSM 17938 daily for 5 days in addition to ORS.

CFU: Colony-forming unit; L. reuteri: Limosilactobacillus reuteri; ORS: Oral rehydration solution.

## BioGaia Protectis<sup>®</sup> is an effective solution for children with acute infectious diarrhea.

74% of children free from watery diarrhea on day 2 in the Protectis group compared to 19% in the placebo group  $^{\rm 24}$ 



BioGaia Protectis<sup>®</sup>: Safe and well tolerated in children under 5 years

L. reuteri DSM 17938

No serious adverse events reported<sup>20,21</sup>

### **BioGaia Protectis®** Gentle Care, Quick Repair



For gentle and quick gut recovery from acute gastroenteritis in children below 5 years of age



BioGaia Protectis® BABY | BioGaia Protectis® KIDS | BioGaia Protectis® MINIPACK





Clinically proven to effectively manage diarrhea 22,24,27-30



Offers rapid relief from diarrheal symptoms within 48 hours<sup>22,24,27-30</sup>



Tackles the main cause of diarrhea and speeds up the return to a balanced gut<sup>31-41</sup>



Safe, natural, and gut-friendly for children<sup>27,42,43</sup>



Formulated with L. reuteri to help restore probiotic supplement the natural balance of gut bacteria<sup>31-42</sup>

#### References

1. Diarrheal disease. WHO. 2017. Available at: https://www.who.int/ news-room/fact-sheets/detail/diarrheal-disease. Accessed on: 16 January 2024.

2. Diarrhea. UNICEF. 2024. Available at: https://data.unicef.org/topic/ child-health/ diarrheal-disease/. Accessed on: 16 January 2024.

 Nemeth V, Pfleghaar N. Diarrhea. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: http://www.ncbi.nlm.nih.gov/ books/NBK448082/. Accessed on: 12 February 2024.

4. Diarrhea. UNICEF and WHO. 2024. Available at: https://www.who.int/ publications/i/item/WHO\_FCH\_CAH\_04.7. Accessed on: 16 January 2024.

 Bartelt LA, Lima AA, Kosek M, et al. "Barriers" to child development and human potential: The case for including the "neglected enteric protozoa" (NEP) and other enteropathy-associated pathogens in the NTDs. PLoS Negl Trop Dis. 2013;7(4):e2125.

 Fan Q, Yi M, Liu H, et al. The impact of age and pathogens type on the gut microbiota in infants with diarrhea in Dalian, China. Can J Infect Dis Med Microbiol. 2020;2020:8837156.

7. Li Y, Xia S, Jiang X, et al. Gut microbiota and diarrhea: An updated review. Front Cell Infect Microbiol. 2021;11:625210.

8. Chung The H,Le SH. Dynamic of the human gut microbiome under infectious diarrhea. Curr Opin Microbiol. 2022;66:79-85.

9. Zinc supplementation in the management of diarrhea. WHO. Available at: https://www.who.int/tools/elena/interventions/zincdiarrhea. Accessed on: 16 January 2024.

10. Lo Vecchio A, Vandenplas Y, Benninga M, et al. An international consensus report on a new algorithm for the management of infant diarrhea. Acta Paediatr. 2016;105(8):e384-e389.

 Szajewska H, Berni Canani R, Domellöf M, et al. Probiotics for the management of pediatric gastrointestinal disorders: Position paper of the ESPGHAN special interest group on gut microbiota and modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247.

 Guarino A, Lo Vecchio A, Dias JA, et al. Universal recommendations for the management of acute diarrhea in non malnourished children. J Pediatr Gastroenterol Nutr. 2018;67(5):586–593.

 Guarner F. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. Available at: https://www. worldgastroenterology.org/guidelines/probiotics-and-prebiotics. Accessed on: 22 January 2024.

14. Cruchet S, Furnes R, Maruy A, et al. The use of probiotics in pediatric gastroenterology: A review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17(3):199–216.

 Iramain R, Jara A, Tovilla YM, et al. Consensus guideline on acute gastroenteritis in the emergency department. Emergency Medicine Committee of SLACIP (Latin American Society of Pediatric Intensive Care). Pediatr (Asunción). 2017;44:249-258.

16. Cameron D, Hock QS, Kadim M, et al. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017;23(45):7952-7964.

17. Saviano A, Brigida M, Migneco A, et al. Lactobacillus Reuteri DSM 17938 (*Limosilactobacillus reuteri*) in diarrhea and constipation: Two sides of the same coin? Medicina (Kaunas). 2021;57(7):643.

 Srinivasan R, Kesavelu D, Veligandla KC, et al. Lactobacillus reuteri DSM 17938: Review of evidence in functional gastrointestinal disorders. Pediatr Ther. 2018;8:3.

 Urbańska M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: A review of the current evidence. Eur J Pediatr. 2014;173(10):1327-1337.

20. Sun X, Kong J, Zhu S, et al. A systematic review and meta-analysis: The therapeutic and preventive effect of *Lactobacillus reuteri* DSM 17938 addition in children with diarrhea. BMC Gastroenterol. 2023;23(1):41.

 Maragkoudaki M, Chouliaras G, Moutafi A, et al. Efficacy of an oral rehydration solution enriched with Lactobacillus reuteri DSM 17938 and zinc in the management of acute diarrhea in InfantisA randomized, double-blind, placebo-controlled trial. Nutrients. 2018;10(9):1189.
Dinleyici EC, PROBAGE Study Group, Vandenplas Y. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhea in hospitalised children. Acta Paediatr. 2014;103(7):e300-e305.

 Dinleyici EC, Dalgic N, Guven S, et al. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J). 2015;91(4):392-396. 24. Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24(4):399-404. doi:10.1097/00005176-199704000-00008.

 Patro-Gołąb B, Szajewska H. Systematic review with meta-analysis: Lactobacillus reuteri DSM 19938 for treating acute gastroenteritis in children. An update. Nutrients. 2019;11(11):2762.

 Szajewska H, Urbańska M, Chmielewska A, et al. Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children.Benef Microbes. 2014;5(3):285-293.

27. Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: *Lactobacillus reuteri* DSM 17938 vs. placebo in children with acute diarnea-a double-blind study. Aliment Pharmacol Ther. 2012;36(4):363–369.

28. Eom T-H, Oh EY, Kim YH, et al. The therapeutic effect of Lactobacillus reuter in acute diarrhoea in infants and toddlers. Korean J Ped. 2005;48:986–989.

29, del Campo R, Garriga M, Pérez-Aragón A, et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: A double blind prospective study.J Cyst Fibros. 20(4):3(6):76-722.

 Garcia Rodenas CL, Lepage M, Ngom-Bru C, et al. Effect of formula containing Lactobacillus reuteri DSM 17938 on fecal microbiota of infants born by cesarean-section. J Pediatr Gastroenterol Nutr. 2016;63(6):681–687.

 Savino F, Fornasero S, Ceratto S, et al. Probiotics and gut health in infants: A preliminary case-control observational study about early treatment with Lactobacillus reuteri DSM 17938. Clin Chim Acta. 2015;451(Pt A):82–87.

32. 34. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126(3):e526-e533.

33. Preidis GA, Hill C, Guerrant RL, et al. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology. 2011;140(1):8-14.

34. Francavilla R, Lionetti E, Castellaneta SP, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study. Helicobacter. 2008;13(2):127-134.

35. Imase K, Tanaka A, Tokunaga K, et al. Lactobacillus reuteri tablets suppress Helicobacter pylori infection-a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi. 2007;81(4):387-393.

36. Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: Incidence of late-onset sepsis and neurological outcome. J Perinatol. 2011;31(1):63-69.

 Betta P, Sciacca P, Trovato L, et al. Probiotics in the prevention of bacterial and Candida infections in newborns submitted to greater surgical interventions and admitted in NICU-retrospective group controlled study. J Pediatr Gastroenterol Nutr. 2007;44:E127.

 Oncel MY, Sari FN, Arayici S, et al. Lactobacillus reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: A randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F110–F115.

39. Preidis GA, Saulnier DM, Blutt SE, et al. Probiotics stimulate enterocyte migration and microbial diversity in the neonatal mouse intestine. FASEB J. 2012;26(5):1960–1969.

40. Indrio F, Di Mauro A, Riezzo G, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: A randomized clinical trial. JAMA Pediatr. 2014;168(3):228–233.

 Roos S, Dicksved J, Tarasco V, et al. 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938. PLoS One. 2013;8(2):e56710.

 Society of Microecology, Chinese Preventive Medical Association.
Evidence-based guideline for pediatric clinical application of probiotics (2023). Chinese Journal of Practical Pediatrics, 2024, 39(1):1-15.

This information material has been produced by BioGaia and has not been reviewed by a healthcare professional. It is only intended for business-to-business and health care professionals i.e. not intended for consumers. BioGaia does not offer any warranties that the information in this material is in accordance with local legislation, this liability lies with BioGaia's partners.